GFAP protein levels in blood fail to predict disease progression in RRMS
Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were associated with the enlargement of brain lesions and of fluid-filled brain cavities called ventricles in people with relapsing-remitting MS (RRMS) undergoing Tysabri (natalizumab) treatment, a study showed. While…